May 9, 2019
Multiple myeloma is a disease characterized by the proliferation of plasma cells which can lead to the abnormally high production of monoclonal immunoglobulins, detected in serum and urine. These plasma cells can enter the bone marrow and replace normal myelopoiesis. Up to 90% of patients progress to bone disease, and for this reason effective imaging...
Continue Reading
Minimal residual disease status appeared prognostic for PFS at three specific time points for patients with multiple myeloma, according to results of a correlative study. “Converting to minimal residual disease (MRD) negative … does not mean [patients] can stop their therapy, but it does convey a significant association with longer survival and long-term PFS,” Theresa Hahn,...
Continue Reading
An investigational BCMA-directed chimeric antigen receptor (CAR) T-cell (CAR-T) therapy, bb2121, appeared safe and effective for previously treated patients with relapsed or refractory multiple myeloma in a phase 1 trial ( identifier: NCT02658929). The trial results were published May 2, 2019, in the New England Journal of Medicine.1 The phase 1 trial, ran by Celgene in collaboration...
Continue Reading

Floor 7, 90 The Terrace
Wellington Central
New Zealand